Characterization of minimal residual disease (MRD) in patients with relapsed/refractory multiple myeloma treated with elranatamab: analysis of MagnetisMM-3

被引：0
|
作者：
Touzeau, Cyrille [1 ]
Weisel, Katja [2 ]
Bahlis, Nizar [3 ]
Quach, Hang [4 ]
Hamilton, Finn [5 ]
Wang, Shen-wu [5 ]
Leip, Eric [5 ]
Viqueira, Andrea [6 ]
O'Brien, Thomas [5 ]
Rodriguez-Otero, Paula [7 ]
机构：
[1] CHU Nantes, Nantes, France
[2] Univ Canc Ctr Hamburg, Hamburg, Germany
[3] Univ Calgary, Arnie Charbonneau Canc Inst, Calgary, AB, Canada
[4] Univ Melbourne, Vincents Hosp Melbourne, Parkville, Vic, Australia
[5] Pfizer Inc, New York, NY USA
[6] Pfizer SLU, Madrid, Spain
[7] Clin Univ Navarra, CIMA, CIBERONC, IDISNA, Pamplona, Spain
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-087
引用
收藏
页码：S82 / S83
页数：2
相关论文
共 50 条
  • [41] The Relationship between Minimal Residual Disease and Patient Reported Outcomes in Relapsed/Refractory Multiple Myeloma
    Avet-Loiseau, Herve
    He, Jianming
    Gries, Katharine S.
    Pei, Huiling
    Saha, Sourish
    Chiu, Christopher
    Cote, Sarah
    Lam, Annette
    BLOOD, 2018, 132
  • [42] Elranatamab, a BCMA-targeted T-cell redirecting immunotherapy, for patients with relapsed or refractory multiple myeloma: Updated results from MagnetisMM-1.
    Jakubowiak, Andrzej J.
    Bahlis, Nizar J.
    Raje, Noopur S.
    Costello, Caitlin
    Dholaria, Bhagirathbhai R.
    Solh, Melhem M.
    Levy, Moshe Y.
    Tomasson, Michael H.
    Dube, Harman
    Damore, Michael A.
    Jiang, Sibo
    Basu, Cynthia
    Skoura, Athanasia
    Chan, Edward Michael
    Trudel, Suzanne
    Chu, Michael P.
    Gasparetto, Cristina J.
    Dalovisio, Andrew Peter
    Sebag, Michael
    Lesokhin, Alexander M.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [43] MagnetisMM-30: A Phase 1B, Open-Label Study of Elranatamab in Combination With Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
    Lesokhin, Alexander
    Raza, Muhammed
    Acosta, Jorge
    Mueller, Patrick Y.
    O'Connell, Ashleigh
    Yver, Anne
    Lou, Carolyn
    Finn, Gregory
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S187 - S187
  • [44] MagnetisMM-30: A phase 1b, open-label study of elranatamab in combination with iberdomide in patients with relapsed or refractory multiple myeloma (RRMM).
    Lesokhin, Alexander M.
    Raza, Muhammed Saleem
    Acosta, Jorge
    Muller, Patrick
    O'Connell, Ashleigh
    Yver, Anne
    Lou, Carolyn
    Finn, Gregory
    Service, Myeloma
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [45] Elranatamab in Combination with Daratumumab for Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 3 Magnetismm-5 Study Safety Lead-in Cohort
    Grosicki, Sebastian
    Mellqvist, Ulf-Henrik
    Pruchniewski, Lukasz
    Crafoord, Jacob
    Trudel, Suzanne
    Min, Chang-Ki
    White, Darrell
    Alegre, Adrian
    Hansson, Markus
    Ikeda, Takashi
    Sunami, Kazutaka
    Leip, Eric
    Kudla, Arthur
    Finn, Gregory
    Koh, Youngil
    BLOOD, 2022, 140 : 4407 - 4408
  • [46] MINIMAL RESIDUAL DISEASE DETECTION BY NEXT GENERATION FLOW-MRD IN MULTIPLE MYELOMA PATIENTS
    Sirianni, S.
    Gozzetti, A.
    Candi, V.
    Bocchia, M.
    Raspadori, D.
    HAEMATOLOGICA, 2016, 101 : S87 - S87
  • [47] MagnetisMM-7: an open label, randomized, phase 3 study of elranatamab versus lenalidomide in patients with newly diagnosed multiple myeloma who are minimal residual disease-positive after transplant
    Mateos, Maria-Victoria
    Lee, Jae Hoon
    Manier, Salomon
    Vandendries, Erik
    Benner, Rebecca
    Yver, Anne
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S45 - S45
  • [48] Efficacy and Safety of Elranatamab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) and Prior B-Cell Maturation Antigen (BCMA)-Directed Therapies: Pooled Analysis From MagnetisMM Studies
    Nooka, Ajay K.
    Lesokhin, Alexander M.
    Mohty, Mohamad
    Niesvizky, Ruben
    Maisel, Christopher
    Arnulf, Bertrand
    Larson, Sarah M.
    Varshavsky-Yanovsky, Asya Nina
    Leleu, Xavier
    Karlin, Lionel
    Vesole, David H.
    Bahlis, Nizar J.
    Fernandez de Larrea, Carlos
    Raje, Noopur
    Leip, Eric
    Conte, Umberto
    Elmeliegy, Mohamed
    Viqueira, Andrea
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S496 - S497
  • [49] Pooled Analysis of MagnetisMM Studies: Efficacy and Safety of Elranatamab in Patients with Relapsed or Refractory Multiple Myeloma (RRMM) Previously Exposed to B-cell Maturation Antigen (BCMA)-Directed Therapies
    Ajay, Nooka K.
    Alexander, Lesokhin M.
    Mahamad, Mohty
    Ruben, Niesvizky
    Christopher, Maisel
    Bertrand, Arnulf
    Sarah, Larson M.
    Nina, Asya Varshavsky-Yanovsky
    Xavier, Leleu
    Lionel, Karlin
    David, Vesole H.
    Nizar, Bahlis J.
    de Larrea Carlos, Fernandez
    Noopur, Raje
    Eric, Leip
    Umbarto, Conte
    Mohamed, Elmeliegy
    Andrea, Viqueira
    Saloman, Manier
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 : S27 - S28
  • [50] MagnetisMM-32: Evaluation of Elranatamab vs EPd, PVd, or Kd in Patients With Relapsed or Refractory Multiple Myeloma and Prior Anti-CD38Directed Therapy
    Schuster, Steven R.
    Ito, Satoshi
    Hoyle, Margaret
    Yver, Anne
    Hong, Fangxin
    Finn, Gregory
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S569 - S569
12345